Videx
Active Ingredient(s): Didanosine, ddIFDA Approved: * October 9, 1991
Pharm Company: * BRISTOL MYERS SQUIBB
Category: HIV / AIDS
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Videx Overview
Didanosine (ddI, DDI), marketed under the trade names Videx, is a medication used to treat HIV/AIDS.[1] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991.[2] Contents 1 Adverse effects 2 Drug interactions 3 Resistance 4 Mechanism of action 5 Pharmacokinetics 6 Histo...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Didanosine
Recent Videx Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Didanosine, ddI
- Capsule, Delayed Rel Pellets: 125mg, 200mg, 250mg, 400mg
- Capsule, Delayed Release : 125mg, 200mg, 250mg, 400mg
- For Solution: 100mg/packet, 10mg/ml, 167mg/packet, 250mg/packet, 375mg/packet
- Powder for Reconstitution: 100mg, 10mg/ml, 167mg, 250mg
- Tablet, Chewable: 100mg, 150mg, 200mg, 25mg, 50mg
NDC Database Records for Videx: (2 results)
Sorted by National Drug Code- 0087-6632 Videx 10 mg/ml Oral Powder, for Solution by Bristol-myers Squibb Company
- 0087-6633 Videx 10 mg/ml Oral Powder, for Solution by Bristol-myers Squibb Company
Other drugs which contain Didanosine, ddI or a similar ingredient: (3 results)
- DIDANOSINE EC Didanosine, ddI
- DIDANOSINE, DDI
- VIDEX EC Didanosine, ddI